Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

GR Thompson; A Soriano; OA Cornely; BJ Kullberg; M Kollef; J Vazquez; PM Honore; M Bassetti; J Pullman; M Chayakulkeeree; I Poromanski; C Dignani; AF Das; T Sandison; PG Pappas; M Akova; R AlAgha; G Alangaden; SJ Albrecht; B Alexander; M Al-Obaidi; G Ambasch; F Armestar Rodriguez; A Azap; A Baffoe-Bonnie; L Belkhir; R Ben-Ami; D Boutoille; A Cascio; LY Chai; R Chaiwarith; S Chen; YC Chen; YH Chen; JY Choi; YH Choi; D Chotiprasitsakul; JW Chung; F Danion; B Denis; E Diaz Santos; MO Dictar; M Diltoer; H Dupont; S Feng; MA Ferre Colomer; R Ferrer; JMFR Forel; J Fortún-Abete; J Garcia-Diaz; M Girardis; F He; M Hites; MW Ho; JP Horcajada Gallego; H Huang; PY Huang; Y Huang; O Hussein; P Intalapaporn; S Jaruratanasirikul; L Jauregui-Peredo; M Johnson; DS Jung; K Jutivorakool; WV Kern; DH Kett; T Khawcharoenporn; YK Kim; P Koehler; A Kotanidou; A Lachiewicz; Q Lin; LE Lopez Cortes; H Luo; R Luzzati; Y Maor; T McCarty; M Merelli; P Merino Amador; J Midturi; GM Migliorino; JP Mira; P Mootsikapun; O Morrissey; P Munoz Garcia de Paredes; C Mussini; E Mylonakis; S Nseir; W Nseir; Z Odabasi; V Papastamopoulos; D Paterson; TF Patterson; KR Peck; Z Peng; N Permpalung; GJ Plantefeve

Journal article

Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

GR Thompson, A Soriano, OA Cornely, BJ Kullberg, M Kollef, J Vazquez, PM Honore, M Bassetti, J Pullman, M Chayakulkeeree, I Poromanski, C Dignani, AF Das, T Sandison, PG Pappas, M Akova, R AlAgha, G Alangaden, SJ Albrecht, B Alexander Show all

Lancet | Published : 2023

DOI: 10.1016/S0140-6736(22)02324-8

Abstract

Background: Rezafungin is a next-generation, once-a-week echinocandin in development for the treatment of candidaemia and invasive candidiasis and for the prevention of invasive fungal disease caused by Candida, Aspergillus, and Pneumocystis spp after blood and marrow transplantation. We aimed to compare the efficacy and safety of intravenous rezafungin versus intravenous caspofungin in patients with candidaemia and invasive candidiasis. Methods: ReSTORE was a multicentre, double-blind, double-dummy, randomised phase 3 trial done at 66 tertiary care centres in 15 countries. Adults (≥18 years) with systemic signs and mycological confirmation of candidaemia or invasive candidiasis were eligibl..

View full abstract